HER2-Negative Breast Cancer Recruiting Phase 1 Trials for Spartalizumab (DB14892)

IndicationStatusPhase
DBCOND0072181 (HER2-Negative Breast Cancer)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03294694Ribociclib + PDR001 in Breast Cancer and Ovarian CancerTreatment